AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Choosing cash back over points can lead to immediate savings. Find out the best scenarios to maximize your financial benefits.
27,195 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Even with a $3 million nest egg, retiring at 50 is not automatic. A rising cost of care, taxes, and the chance of mar...
SpaceX could become one of the biggest IPOs in history. This guide breaks down what to watch, what it means for your ...
Public firms are embracing bitcoin as a reserve asset to diversify treasury holdings and hedge inflation. This report...
ONEOK posted robust Q4 2025 results, boosting full-year EBITDA, trimming debt, and highlighting synergies from recent...
High-income investors face a tax cliff with JEPI: the 8% distribution yield is largely ordinary income, trimming real...
GPIQ has drawn billions with a near-10% yield by selling call options on mega-cap tech. The strategy injects income b...
Joby Aviation is set to report Q4 2025 results after the market close tonight. Analysts will track revenue, cash burn...
A long-running dividend ETF marks 22 years of payments as retirees continue to seek steady income in a shifting marke...
Retail traders on Robinhood are flocking to a high-yield FANG income ETF, chasing monthly payouts even as upside is c...
If you rely on Social Security, the 2027 COLA forecast isn't just a number—it's a planning tool. This article breaks ...
A federal judge found the IRS violated privacy laws by sharing confidential taxpayer information with ICE, revealing ...